JUPITER NEUROSCIENCES, INC. — SEC Form D Filing

JUPITER NEUROSCIENCES, INC. filed an SEC Form D on September 4, 2026, reporting $775K raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
September 4, 2026
Amount reported
$775K
Round stage
Pre-Seed
Industry
Biotechnology
Website
https://jupiterneurosciences.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Patients suffer from neuroinflammation, Alzheimer’s disease, and various rare diseases, which current treatments may not adequately address or may cause significant gastrointestinal side effects.

Solution

Jupiter Neurosciences is developing JOTROL™, a clinical-stage drug platform based on a patented micellar form of resveratrol, delivered as an oral softgel that can safely reach therapeutic levels and cross the blood-brain barrier to treat these conditions.

Why now

Advances in understanding neuroinflammation and the limitations of current treatments for diseases like Alzheimer's create a critical need for innovative drug delivery platforms and therapeutic compounds that can effectively target the central nervous system.

Verdict

This cleared because the novel delivery mechanism for a known compound, potentially crossing the blood-brain barrier, presented a clear, de-risked path to addressing significant unmet medical needs. Investors were implicitly betting on the technical feasibility of achieving therapeutic levels with reduced side effects in a complex disease area, rather than on the discovery of an entirely new molecule. The reliance on resveratrol, while offering a known safety profile, inherently limited the perceived upside by associating it with a widely available, unproven supplement.

Source: SEC EDGAR Form D filing